CHUKYOIYAKUHIN CO.,LTD. Logo

CHUKYOIYAKUHIN CO.,LTD.

Offers health products and pharmaceuticals via a direct-to-home placement service.

4558 | T

Overview

Corporate Details

ISIN(s):
JP3519900009
LEI:
Country:
Japan
Address:
半田市亀崎北浦町2丁目15番地の1

Description

CHUKYOIYAKUHIN CO.,LTD. specializes in a direct-to-customer sales model centered on regular home visits, providing what it terms "Total Life Care." A core service is its placement medicine system, where a selection of pharmaceuticals and health products is left in customers' homes for their convenience, with payment collected for consumed items during subsequent visits. Operating under the principle that "prevention is better than cure," the company offers a diverse product portfolio that extends beyond pharmaceuticals to include health foods, beverages, medical equipment, cosmetics, and other daily necessities to support the overall well-being of its household customers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-06-29 04:42
確認書
Japanese 8.2 KB
2022-06-29 04:41
有価証券報告書-第44期(令和3年4月1日-令和4年3月31日)
Japanese 915.2 KB
2022-02-10 06:23
四半期報告書-第44期第3四半期(令和3年10月1日-令和3年12月31日)
Japanese 173.9 KB
2021-11-12 06:24
四半期報告書-第44期第2四半期(令和3年7月1日-令和3年9月30日)
Japanese 201.1 KB
2021-08-11 08:20
四半期報告書-第44期第1四半期(令和3年4月1日-令和3年6月30日)
Japanese 160.9 KB
2021-06-28 04:41
内部統制報告書-第43期(令和2年4月1日-令和3年3月31日)
Japanese 22.1 KB
2021-06-28 04:39
確認書
Japanese 8.1 KB
2021-06-28 04:38
有価証券報告書-第43期(令和2年4月1日-令和3年3月31日)
Japanese 854.6 KB
2021-02-12 06:26
四半期報告書-第43期第3四半期(令和2年10月1日-令和2年12月31日)
Japanese 168.0 KB
2021-01-08 07:02
有価証券届出書(組込方式)
Japanese 217.8 KB
2020-11-13 07:02
四半期報告書-第43期第2四半期(令和2年7月1日-令和2年9月30日)
Japanese 194.1 KB
2020-08-07 08:01
四半期報告書-第43期第1四半期(令和2年4月1日-令和2年6月30日)
Japanese 148.8 KB
2020-08-05 09:16
訂正有価証券報告書-第42期(平成31年4月1日-令和2年3月31日)
Japanese 516.2 KB
2020-08-05 09:11
訂正四半期報告書-第42期第3四半期(令和1年10月1日-令和1年12月31日)
Japanese 113.1 KB
2020-08-05 09:07
訂正四半期報告書-第42期第2四半期(2019/07/01-2019/09/30)
Japanese 133.5 KB

Automate Your Workflow. Get a real-time feed of all CHUKYOIYAKUHIN CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CHUKYOIYAKUHIN CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CHUKYOIYAKUHIN CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.